Genomic Vision announced on Thursday the expansion of its RCA service offering, a technology that monitors the spatial and temporal characteristics of genomic DNA replication, with the aim of meeting the growing needs of the industry.

The biotech company explains that it will now be able to provide its customers with new parameters such as fork speed, analog ratio, fork symmetry, fork stall and new origin initiation.

It will also offer a new service called 'Locus-RCA', which is attracting growing interest in the scientific community as a means of assessing changes in replication dynamics in a specific region of the genome, such as oncogenes and tumor suppressor genes

In a press release, Genomic explains that this service offering is aimed in particular at oncology and drug discovery.

This announcement comes at a time when sales linked to the RCA service have increased by more than 60% in one year.

Between 2022 and 2023, Genomic Vision claims to have outperformed the pharmaceutical industry sector, while seeing a steady growth in the number of requests from academic laboratories.

Following these announcements, the share price climbed by over 12% on Thursday on Euronext Paris, although it is still down around 95% since the start of the year.

Copyright (c) 2023 CercleFinance.com. All rights reserved.